Dr. Charles J. Parker, MD

Dr. Parker practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Parker's NPI, 1790735686, was assigned on May 11, 2006. Dr. Parker graduated from University of North Carolina at Chapel Hill School of Medicine in 1975. Dr. Parker holds Utah license 173510-1205.

Dr. Parker's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Parker's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Parker is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Parker to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Parker practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Parker's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Parker is licensed in Utah.

CMS data shows 133 Medicare services from Dr. Parker across 4 procedure codes in 2024, for 63 Medicare patients. Medicare paid $7,919 for them. Every service was in an office.

CMS counts 63 Medicare patients who saw Dr. Parker in 2024. The largest group is 65 to 74, with 28 patients. 68% of them have high blood pressure, and 57% have high cholesterol. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Parker's median patient age at 74, with 43% women.

In 2024, Dr. Parker wrote 51 Medicare Part D claims for 12 patients. 73% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $38,740 in total drug cost. In 2023, CMS named 26 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Parker for performance year 2024, reported as part of a group. Dr. Parker accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 26 papers to Dr. Parker, published from 2005 to 2025. 2016 was the busiest year, with 3. The most frequent topics are Protoporphyria, Erythropoietic, 5-Aminolevulinate Synthetase and Liver. Dr. Parker has published most often in N Engl J Med. Dr. Parker's most frequent co-authors are Herbert L. Bonkovsky, MD, Robert J. Desnick, PhD, MD and Gordon Douglas Mclaren, MD.

Dmand AI links Dr. Parker to 1 clinical trial. Conditions studied include Protoporphyria, Erythropoietic and Porphyrias.

CMS Open Payments shows 46 general payments to Dr. Parker from 7 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 65% of the total. Genentech, Inc. paid the most, $43,934.

Dr. Parker graduated from University of North Carolina at Chapel Hill School of Medicine in 1975.